Skip to content

The Effects of Oliceridine and Sufentanil on Postoperative Nausea and Vomiting in Abdominal Surgery: A Prospective, Multicenter, Double-Blind, Randomized Controlled Superiority Trial

The Effects of Oliceridine and Sufentanil on Postoperative Nausea and Vomiting in Abdominal Surgery: A Prospective, Multicenter, Double-Blind, Randomized Controlled Superiority Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089262
Enrollment
Unknown
Registered
2024-09-04
Start date
2024-12-05
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Oliceridine Group:Oselidine 0.05mg/kg was used for anesthesia induction, 1mg of oselidine was added every 2 hours and 10 minutes before the end of the operation, and oselidine 0.4mg/kg was used for po
Sufentanil Group:Sufentanil 0.5 µg/kg was used for anesthesia induction, 10 µg of sufentanil was added every 2 hours and 10 minutes before the end of the operation, and sufentanil was used 2 µg/kg for

Sponsors

Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-65 years; 2) ASA grade I-III; 3) BMI 18.5-23.9 kg/m²; 4) Patients undergoing elective general abdominal surgery who require postoperative patient-controlled intravenous analgesia (PCIA); 5) Voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Chronic pain, long-term use of analgesics and psychotropic drugs, or alcohol abuse; 2) Allergy to the study drug or any contraindications; 3) Patients in shock, with mental abnormalities, or cognitive impairment who cannot cooperate; 4) Severe heart disease, liver disease, or kidney disease; 5) Acute or chronic bronchial asthma; 6) Suspected gastrointestinal obstruction; 7) Prolonged QT interval on ECG or presence of ventricular arrhythmias; 8) Concurrent use of drugs known to prolong the QT interval (e.g., moxifloxacin, quinidine, amiodarone, etc.); 9) Untreated hypokalemia or hypomagnesemia; 10)P regnancy, breastfeeding, or planned pregnancy; 11) Sleep apnea; 12) Participation in other drug trials within the past three months.

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative nausea and vomiting (PONV) within 48 hours after surgery;

Secondary

MeasureTime frame
The number of vomits within 48 hours after surgery.;The degree of nausea within 48 hours after surgery;The dose and proportion of patients using antiemetics within 48 hours after surgery;Resting NRS pain score within 48 hours after surgery;The dose and proportion of patients using rescue analgesics within 48 hours after surgery;The number of effective presses and drug consumption of the analgesia pump;Incidence of other opioid-related adverse reactions: Hypoxemia depression, pruritus, dizziness, headache;Time to first postoperative flatus;Quality of recovery after surgery (QoR-15 score);Total length of hospital stay;

Countries

China

Contacts

Public ContactXu Tao

Changhai Hospital

taoxu_smmu@163.com+86 135 0197 6460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026